ZARCONE DONNA F

SEC source: 0001402057-20-000090 · wf-form4_158396263406628.xml · nonDerivative · entry 2

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,118.24

F2 · shares: Dividend equivalents awarded pursuant to outstanding restricted stock unit awards previously granted under the CDW Corporation 2013 Long-Term Incentive Plan.

SEC source: 0001402057-20-000090 · wf-form4_158396263406628.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,045.08

F1 · shares: This is a grant of restricted stock units under the CDW Corporation 2013 Long-Term Incentive Plan. The restricted stock units vest on March 9, 2021 and settlement into shares of CDW Corporation common stock has been deferred until the sooner of separation from service on the Board of Directors or five years following vesting.

SEC source: 0001225208-20-004188 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,059

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001402057-19-000257 · wf-form4_157618927590070.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,492.08

F1 · shares: Dividend equivalents awarded pursuant to outstanding restricted stock unit awards previously granted under the CDW Corporation 2013 Long-Term Incentive Plan.

SEC source: 0001225208-19-015095 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,800

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001402057-19-000206 · wf-form4_156823408045454.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,440.48

F1 · shares: Dividend equivalents awarded pursuant to outstanding restricted stock unit awards previously granted under the CDW Corporation 2013 Long-Term Incentive Plan.

SEC source: 0001225208-19-012172 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,563

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001402057-19-000163 · wf-form4_156045862248810.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,391.83

F1 · shares: Dividend equivalents awarded pursuant to outstanding restricted stock unit awards previously granted under the CDW Corporation 2013 Long-Term Incentive Plan.

SEC source: 0001225208-19-008814 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,255

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001402057-19-000131 · wf-form4_155259872046889.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,340.73

F1 · shares: Dividend equivalents awarded pursuant to outstanding restricted stock unit awards previously granted under the CDW Corporation 2013 Long-Term Incentive Plan.

SEC source: 0001402057-19-000096 · wf-form4_155208247281127.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,284.57

F1 · shares: This is a grant of restricted stock units under the CDW Corporation 2013 Long-Term Incentive Plan. The restricted stock units vest on February 25, 2020 and settlement into shares of CDW Corporation common stock has been deferred until the sooner of separation from service on the Board of Directors or five years following vesting.

SEC source: 0001225208-19-004409 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,935

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001567619-18-008666 · doc1.xml · derivative · entry 2

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $.25 Par Value · 2,797 shares

Expires not disclosed

F3 · security: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_price: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · kind: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · price: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_date: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.expiration_date: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

SEC source: 0001567619-18-008666 · doc1.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-18-008716 · doc1.xml · derivative · entry 2

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,797

Underlying: Common Stock, $0.01 Par Value · 2,797 shares

Expires not disclosed

F3 · security: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_price: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · kind: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · price: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_date: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.expiration_date: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

SEC source: 0001567619-18-008716 · doc1.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,663

F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001402057-18-000268 · wf-form4_154465122211871.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,688.57

F1 · shares: Dividend equivalents awarded pursuant to the terms of previously granted restricted stock units.

SEC source: 0001225208-18-016223 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,663

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001402057-18-000216 · wf-form4_153678530803642.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,634.45

F1 · shares: Dividend equivalents awarded pursuant to the terms of previously granted restricted stock units.

SEC source: 0001225208-18-013185 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,462

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001402057-18-000149 · wf-form4_152892246986696.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,595.09

F1 · shares: Dividend equivalents awarded pursuant to the terms of previously granted restricted stock units.

SEC source: 0001225208-18-010124 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,224

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001402057-18-000102 · wf-form4_152097433041722.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,554.02

F1 · shares: Dividend equivalents awarded pursuant to the terms of previously granted restricted stock units.

SEC source: 0001402057-18-000062 · wf-form4_152002804200181.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,508

F1 · shares: This is a grant of restricted stock units under the CDW Corporation 2013 Long-Term Incentive Plan. The restricted stock units vest on the first anniversary of the date of grant and settlement into shares of CDW Corporation common stock has been deferred until the sooner of separation of service on the Board of Directors or five years following vesting.

SEC source: 0001225208-18-005162 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,959

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's preliminary proxy statement filed with the SEC on March 2, 2018.

SEC source: 0001225208-18-001172 · doc4.xml · nonDerivative · entry 2

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2017.

F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $215.00 to $215.315 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001225208-18-001172 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,971

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2017.

F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $216.005 to $216.24 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001402057-17-000204 · wf-form4_151319998499872.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,637

F1 · shares: Dividend equivalents awarded pursuant to the terms of previously granted restricted stock units.

SEC source: 0001225208-17-018128 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,730

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001402057-17-000144 · wf-form4_150533634060628.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,593.41

F1 · shares: Dividend equivalents awarded pursuant to the terms of previously granted restricted stock units.

SEC source: 0001225208-17-014583 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,518

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001402057-17-000087 · wf-form4_149738770317511.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,554.58

F1 · shares: Dividend equivalents awarded pursuant to the terms of outstanding restricted stock units.

SEC source: 0001225208-17-010848 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,271

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001402057-17-000043 · wf-form4_148952776401646.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,477.39

F1 · shares: This is a grant of restricted stock units under the CDW Corporation 2013 Long-Term Incentive Plan. The restricted stock units vest on the first anniversary of the date of grant and settlement into shares of CDW Corporation common stock has been deferred until the sooner of separation of service on the Board of Directors or five years following vesting.

SEC source: 0001402057-17-000043 · wf-form4_148952776401646.xml · nonDerivative · entry 2

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,510.2

F2 · shares: Dividend equivalents awarded pursuant to the terms of previously granted restricted stock units.

SEC source: 0001225208-17-005384 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,992

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 72 of Cigna's proxy statement filed with the SEC on March 18, 2016.

SEC source: 0001225208-16-042628 · doc4.xml · nonDerivative · entry 1

ZARCONE DONNA F · CIK 0001243083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,690

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 72 of Cigna's proxy statement filed with the SEC on March 18, 2016.